Related Experiment Video
Updated: Feb 17, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.7K
PCSK9 signaling pathways and their potential importance in clinical practice
Michał Wiciński1, Jarosław Żak1, Bartosz Malinowski1
1Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium, Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-090 Bydgoszcz, Poland.
The EPMA Journal
|December 7, 2017
Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is key in LDL metabolism and cardiovascular health. PCSK9 inhibitors show potential in reducing cardiovascular events but require further research regarding efficacy and immunogenicity.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Pharmacology
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial regulator of low-density lipoprotein (LDL) receptor metabolism.
- PCSK9 influences LDL cholesterol levels and plays a role in inflammatory processes within atherosclerotic plaques.
- Dysregulation of PCSK9 is implicated in cardiovascular disease and metabolic disorders like diabetes.
Purpose of the Study:
- To review the structure, biochemical pathways, and functions of PCSK9.
- To explore the role of PCSK9 in LDL metabolism and its impact on cardiovascular health.
- To discuss the significance and potential of PCSK9-targeted therapies.
Main Methods:
- Literature review of PCSK9 structure, function, and targeted treatments.
- Analysis of PCSK9 interactions with LDL receptors and other proteins.
- Examination of PCSK9's role in inflammation, metabolic pathways, and oncogenesis.
Main Results:
- PCSK9 regulates LDL receptor degradation, impacting plasma LDL cholesterol levels.
- PCSK9 inhibition, particularly with monoclonal antibodies, has demonstrated reductions in cardiovascular events and mortality.
- Emerging strategies include mRNA silencing and peptide-based inhibitors targeting PCSK9.
Conclusions:
- PCSK9 is a significant therapeutic target for hypercholesterolemia and cardiovascular disease.
- While PCSK9 inhibitors offer promise, considerations regarding immunogenicity and long-term efficacy are crucial.
- Further research is needed to fully elucidate PCSK9's complex roles and optimize therapeutic strategies.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
10
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
10
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
01:19Interactions Between Signaling Pathways
7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
19
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
19
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
20
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
20
01:29Pharmacogenetics and Pharmacogenomics: Overview
13
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
13